C5 and COVID-19: Consistent with both such evidence and the high C5a levels described in preclinical models of acute lung diseases due to pathogenic viruses, including SARS-CoV, the C5a–C5aR1 axis has been thought as a target for a potential therapeutic strategy to treat severe COVID-19 [49].